Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Health technology assessment (Winchester, England)

Volumn 14 Suppl 1, Issue , 2010, Pages 31-38

  Greenhalgh, J ^a   Bagust, A ^b   Boland, A ^b   Saborido, C M ^b   Fleeman, N ^b   McLeod, C ^b   Dundar, Y ^b   Dickson, R ^b   Proudlove, C ^b   Kolamunnage Dona, R ^b   Fisher, M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED KINGDOM;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; THIOPHENES; TICLOPIDINE;

EID: 84886943100     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl1/05     Document Type: Review

References (62)